http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
토양 방선균 KRA16-334 배양 여액의 돼지풀 방제효과
김재덕(Jae-Deok Kim),김영숙(Young-Sook Kim),장경수(Kyoung-Soo Jang),임희경(He-Kyoung Lim),박기웅(Kee Woong Park),임정현(Jeong-Hyun Lim),전경미(Kyong-Mi Chon),최정섭(Jung-Sup Choi) 한국잡초학회 2021 Weed & Turfgrass Science Vol.10 No.3
토양 방선균 KRA16-334 균주 배양여액의 돼지풀에 대한 방제효과를 온실 및 포장조건에서 수행하여 돼지풀 방제제 후보소재로서의 가능성을 검토하였다. 본 균주 배양 여액은 온실조건에서 돼지풀 초·중·후기 경엽처리 시 처리 농도범위에서 우수한 방제 활성을 보였으며, 2회 체계처리에서 4배 희석액 처리농도까지 우수한 방제효과를 나타내었다. 선발 균주 KRA16-334 배양여액의 돼지풀에 대한 살초특성은 속효성이었고 약효가 2주 이상 지속되는 특성을 확인하였다. 외형적으로는 처리 초기에 황화 증상이 발현되었다가 고사로 진행되어 사멸되는 양상을 보였다. 선발 후보소재 토양 방선균 KRA16-334 균주는 국내 환경 및 식생 조건에서 생태계교란 광엽잡초인 돼지풀에 대한 친환경적인 방제제로서 유용하게 활용할 수 있을 것으로 기대된다. Ambrosia artemisifilia (Rag weed) is one of the first ecosystem-disrupting plant designated by the Ministry of Environment, and it is found to be distributed in the largest area among ecosystem-disrupting plants in Korea. This study was conducted to control A. artemisiifilia with KRA16-334 broth filtrate. The broth filtrate of the KRA16-334 was applied to A. artemisiifilia in a greenhouse. The results showed that the foliar applications of KRA16-334 broth filtrate at all application rates demonstrated excellent herbicidal activity against the early (2-3 Ls), middle (4-5 Ls), and late (7-8 Ls) stages of A. artemisiifilia. Two times of KRA16-334 broth filtrate application suppressed regrwoth of A. artemisiifilia shoot. The main symptom of external manifestation was water soaked dots within 24 hours after treatment and continued to the appearance of chlorosis and proceeded to leaf burn-down, ultimately defoliations to dead plants. Our results show that the KRA16-334 broth filtrate can be utilized as a natural and eco-friendly herbicide against A. artemisiifilia that is one of the broad-leaved weeds disturbing Korean ecosystems.
인체에 적용한 전기자극이 Serum myoglobin과 Aldolase에 미치는 영향에 대한 생리학적 효과
김순희,천기영,최영덕,Kim, Soon-Hee,Chon, Ki-Young,Choi, Young-Deok 대한물리치료과학회 1999 대한물리치료과학회지 Vol.6 No.3
Prior studies have revealed that several stimulation to the muscle have released serum myoglobin into the blood vessel and increased aldolase activity. The present authors carried out a study which effect of electrical stimulation treatment (induced a isotonic wrist exerceise) on serum myoglobin(Mb) levels and aldolase(Al) activity were investigated in 6 healthy female. There were four groups of female: 1. no electrical stimulation control: 2. electrical stimulation 10min (EST10'); 3. electrical stimulation 20 min (EST20'); 4. electrical stimulation 30min (EST30'). Each groups is all the same one. Radioimmunoassay and Ultraviolet Spectrophotometry were performed to increased or decreased of serum myoglobin and aldolase. Serum myoglobin significantly increased in electrical stimulated groups[EST10' $(30.20{\pm}5.27ng/ml)$, EST20'$(31.65{\pm}3.96ng/ml)$, EST30'$(31.95{\pm}2.0ng/ml)$] to be compared with control group$(24.43{\pm}2.20ng/ml)$. Aldolase significantly increased in electrical stimulated groups [EST10' ($6.85{\pm}1.17$ Sigma U/mL), EST20'($6.70{\pm}1.46$ Sigma U/mL), EST30'($6.56{\pm}1.01$ Sigma U/mL)) to be compared with control group($5.03{\pm}1.86$ Sigma U/mL). The results of this study show that isotonic exercise result in electrical stimulation treatment increased serum myoglobin content and aldolase activity. In conclusion, our results support that stimulation release serum myoglobin and increase aldolase activity.
효모 중 아스코르브산을 포함하는 혼합기능 산화계를 억제하는 새로운 항산화 단백질의 존재에 관한 연구
김강화,조남철,전덕영 ( Kang Hwa Kim,Nam Chul Cho,Deok Young chon ) 생화학분자생물학회 1990 BMB Reports Vol.23 No.3
Antioxidant activity which specifically inhibits the mixed-function oxidation(MFO) system comprised of ascorbate, Fe(III), and O₂ was found from both extracts of Saccharomyces cerevisiae and Candida pseudotropicalis. From crude extracts of the yeast three different antioxidant activities against MFO systems containing dithiothreitol (DTT) or ascorbate as an electron donor could be separated by a HPLC-DEAE column chromatography. Antioxidant activity of the fraction eluted at 0.22 M potassium chloride from both yeast preparations selectively inhibited the ascorbate/Fe(III)/O₂ MFO system. It differed from catalase activity which inhibits DTT/Fe(III)/O₂ and ascorbate/Fe(III)/O₂ MFO systems with similar extent and thiol-specific antioxidant activity which was reported from S. cerevisiae and inhibits DTT/Fe(III)/O₂ MFO system specifically. The active fraction showed no catalase activity and did not carry immunoreactive protein which specifically reacts with antibody against thiol-specific antioxidant protein. The results suggest that there is another type of antioxidant protein besides catalase and thiol-specific antioxidant protein in yeast.
Capeding, Maria Rosario,Teshome, Samuel,Saluja, Tarun,Syed, Khalid Ali,Kim, Deok Ryun,Park, Ju Yeon,Yang, Jae Seung,Kim, Yang Hee,Park, Jiwook,Jo, Sue-Kyoung,Chon, Yun,Kothari, Sudeep,Yang, Seon-Young Elsevier Science 2018 Vaccine Vol.36 No.26
<▼1><P><B>Highlights</B></P><P>•<P>Vi-DT is safe and well tolerated in participants aged 2–45 years.</P>•<P>Significantly higher immune responses post Vi-DT compared to Vi polysaccharide vaccine.</P>•<P>No further increase in GMT post second dose as compared to post first dose of Vi-DT.</P></P></▼1><▼2><P><B>Background</B></P><P>Typhoid fever remains a major public health problem in low- and middle-income countries where children aged 2–14 years bear the greatest burden. Vi polysaccharide is poorly immunogenic in children <2 years of age, and protection in adults is modest. The limitations of Vi polysaccharide vaccines can be overcome by conjugation of the Vi to a carrier protein. A typhoid conjugate vaccine composed of Vi polysaccharide conjugated to diphtheria toxoid (Vi-DT) has been developed. The Phase I study results are presented here.</P><P><B>Methods</B></P><P>This was a randomized, observer-blinded Phase I study to assess the safety and immunogenicity of Vi-DT compared to Vi polysaccharide vaccine, conducted in Manila, Philippines. Participants enrolled in an age de-escalation manner (18–45, 6–17 and 2–5 years) were randomized between Test (Vi-DT, 25 µg) administered at 0 and 4 weeks and Comparator (Vi polysaccharide, Typhim Vi® and Vaxigrip®, Sanofi Pasteur) vaccines.</P><P><B>Results</B></P><P>A total of 144 participants were enrolled (48 by age strata, 24 in Test and Comparator groups each). No serious adverse event was reported in either group. Solicited and unsolicited adverse events were mild or moderate in both groups with the exception of a 4-year old girl in Test group with grade 3 fever which resolved without sequelae. All participants in Test group seroconverted after first and second doses of Vi-DT while the proportions in the Comparator group were 97.1% and 97.2%, after first dose of Typhim Vi® and second dose of Vaxigrip®, respectively. Vi-DT showed 4-fold higher Geometric Mean Titers (GMT) compared to Typhim Vi® (adjusted for age strata, p < 0.001). No further increase of GMT was detected after the second dose of Vi-DT. Anti-DT IgG seroresponse rates were 81.2% and 84.5% post first and second Vi-DT doses, respectively.</P><P><B>Conclusions</B></P><P>Vi-DT vaccine was safe, well-tolerated and immunogenic in participants aged 2–45 years.</P><P>ClinicalTrials.gov registration number: NCT02645032.</P></▼2>